Macrophage activation syndrome in the acute phase of Kawasaki disease

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 7, 2010, Pages 527-531

  Latino, Giuseppe A ^a   Manlhiot, Cedric ^a   Yeung, Rae S M ^a   Chahal, Nita ^a   McCrindle, Brian W ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Hemophagocytic syndrome; Kawasaki disease; Macrophage activation syndrome; Steroids

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CYCLOSPORIN A; D DIMER; DEXAMETHASONE; IMMUNOGLOBULIN; LIVER ENZYME; MEPREDNISONE; PREDNISONE; BIOLOGICAL MARKER; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ARTICLE; BONE MARROW BIOPSY; CHILD; CLINICAL ARTICLE; CONVALESCENCE; CYTOPENIA; DISEASE COURSE; ERYTHROPHAGOCYTOSIS; FEMALE; FEVER; HEPATOSPLENOMEGALY; HUMAN; HYPERFERRITINEMIA; HYPERTRIGLYCERIDEMIA; HYPOFIBRINOGENEMIA; INFANT; LYMPH NODE BIOPSY; MACROPHAGE ACTIVATION SYNDROME; MALE; MEDICAL RECORD REVIEW; MUCOCUTANEOUS LYMPH NODE SYNDROME; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; ACUTE DISEASE; COMORBIDITY; PHAGOCYTOSIS;

ACUTE DISEASE; ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MACROPHAGE ACTIVATION SYNDROME; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PHAGOCYTOSIS; RETROSPECTIVE STUDIES;

EID: 77958172767     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181dccbf4     Document Type: Article

References (21)

1. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708-1733. (Pubitemid 41754943)
2. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol. 2002;14:548-552.
3. Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J. 2003;22: 663-666.
4. Ohga S, Ooshima A, Fukushige J, et al. Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state. Eur J Pediatr. 1995;154:539-541.
5. Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics. 2003;112(6 Pt 1):e495.
6. Kaneko K, Takahashi K, Fujiwara S, et al. Kawasaki disease followed by haemophagocytic syndrome. Eur J Pediatr. 1998; 157:610-611.
7. al-Eid W, al-Jefri A, Bahabri S, et al. Hemophagocytosis complicating Kawasaki disease. Pediatr Hematol Oncol. 2000; 17:323-329.
8. Cummings C, McCarthy P, van Hoff J, et al. Kawasaki disease associated with reactive hemophagocytic lymphohistiocytosis. Pediatr Infect Dis J. 2008;27:1116-1118.
9. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007;166:95-109.
10. Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis. 2003;36:306-312.
11. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85:421-426.
12. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129: 750-754.
13. Henter JI, Arico M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol. 1997;28: 342-347.
14. Gupta AA, Tyrrell P, Valani R, et al. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution. J Pediatr Hematol Oncol. 2009;31:81-84.
15. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747-2771. (Pubitemid 39453026)
16. Manlhiot C, Yeung RS, Clarizia NA, et al. Kawasaki disease at the extremes of the age spectrum. Pediatrics. 2009;124: e410-e415.
17. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598-604.
18. Arico M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996;10:197-203.
19. Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol. 2007;19:477-481.
20. Sabharwal T, Manlhiot C, Benseler SM, et al. Comparison of factors associated with coronary artery dilation only versus coronary artery aneurysms in patients with Kawasaki disease. Am J Cardiol. 2009;104:1743-1747.
21. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615-620.